EUVIMEDEUVIMED entdecken
Vergleichsstudie

Induction chemoimmunotherapy followed by radiotherapy and consolidation immunotherapy versus definitive concurrent chemoradiotherapy with consolidation immunotherapy for unresectable stage III non‐small cell lung cancer: A single‐center retrospective study

Hanjun Mo iD, Yiping Zhang iD, Zhuoying Tian iD, Pengfei Yue, Min Hu, Yaqin Zhao, Feng Luo, Cheng Yi iD, Yan Li iD

International Journal of Cancer · 15.04.2026 · 158 (8) · 2148-2158

DOI: 10.1002/ijc.70238 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift International Journal of Cancer, online erschienen am 07.11.2025. Verfasst von Hanjun Mo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Abdominal Oncology Ward, Division of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Chemoradiotherapy, Immunotherapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Science and Technology Department of Sichuan Province, West China Hospital, Sichuan University, Project of Natural Science Foundation of Sichuan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In clinical practice, patients with unresectable stage III non‐small cell lung cancer (NSCLC) often exhibit limited tolerance to concurrent chemoradiotherapy (cCRT). This retrospective study evaluated the efficacy and safety of induction chemoimmunotherapy followed by definitive radiotherapy (RT) and consolidation immunotherapy, compared with standard cCRT plus consolidation immunotherapy. A total of 102 patients treated at West China Hospital between June 2019 and June 2024 were analyzed. Primary endpoints were overall survival (OS) and progression‐free survival (PFS); secondary endpoints included objective response rate (ORR), disease control rate (DCR), and treatment‐related adverse events (TRAEs). Survival outcomes were comparable between groups (median OS: not reached vs. 36 months, p = 0.52; median PFS: 25 vs. 28 months, p = 0.71), with higher 3‐year OS observed in the induction group (61.4% vs. 38.3%). In the induction group, ORR after systemic therapy was 74.2%, and post‐RT DCR reached 83.3%. TRAEs were comparable across groups, with pneumonitis being the most frequent toxicity and no significant increase in grade ≥3 events observed. These findings support the induction‐based sequential strategy as a viable alternative to cCRT for patients with unresectable stage III NSCLC, especially those unsuitable for concurrent treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsChemoradiotherapyImmunotherapyConsolidation ChemotherapyInduction ChemotherapyHumansRetrospective StudiesMaleFemaleMiddle AgedAgedNeoplasm StagingAdultProgression-Free Survival

Stichwörter der Autor:innen

concurrent chemoradiotherapyimmune checkpoint inhibitorsinduction chemoimmunotherapynon‐small cell lung cancerradiotherapy

Autor:innen und Institutionen

  • Abdominal Oncology Ward, Division of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Lung Cancer Center, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital of Sichuan University, Chengdu, China.
  • Clinical Medical College, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
  • Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

ORCID-Profile: Hanjun Mo, Yiping Zhang, Zhuoying Tian, Cheng Yi, Yan Li

Förderung

  • Science and Technology Department of Sichuan Province
  • West China Hospital, Sichuan University
  • Project of Natural Science Foundation of Sichuan Province
  • Wu Jieping Medical Foundation

Zitieren

APA

Mo, H., Zhang, Y., Tian, Z., Yue, P., Hu, M., Zhao, Y., Luo, F., Yi, C., & Li, Y. (2026). Induction chemoimmunotherapy followed by radiotherapy and consolidation immunotherapy versus definitive concurrent chemoradiotherapy with consolidation immunotherapy for unresectable stage III non‐small cell lung cancer: A single‐center retrospective study. International Journal of Cancer, 158(8), 2148-2158. https://doi.org/10.1002/ijc.70238

Vancouver

Mo H, Zhang Y, Tian Z, Yue P, Hu M, Zhao Y, et al. Induction chemoimmunotherapy followed by radiotherapy and consolidation immunotherapy versus definitive concurrent chemoradiotherapy with consolidation immunotherapy for unresectable stage III non‐small cell lung cancer: A single‐center retrospective study. International Journal of Cancer. 2026;158(8):2148-2158. doi:10.1002/ijc.70238

BibTeX
@article{Mo2026,
  author = {Mo, Hanjun and Zhang, Yiping and Tian, Zhuoying and Yue, Pengfei and Hu, Min and Zhao, Yaqin and Luo, Feng and Yi, Cheng and Li, Yan},
  title = {Induction chemoimmunotherapy followed by radiotherapy and consolidation immunotherapy versus definitive concurrent chemoradiotherapy with consolidation immunotherapy for unresectable stage III non‐small cell lung cancer: A single‐center retrospective study},
  journal = {International Journal of Cancer},
  year = {2026},
  volume = {158},
  number = {8},
  pages = {2148--2158},
  doi = {10.1002/ijc.70238}
}
Kostenlos starten →